Los Angeles, California – Champions Oncology, Inc. (NASDAQ: CSBR) held its Q1 2025 Earnings Conference Call on September 11, 2024, at 4:30 PM ET. During the call, Ronnie Morris, the Chief Executive Officer, and David Miller, the Chief Financial Officer, provided insights into the company’s financial performance for the first quarter.

Morris began by addressing the challenges faced by Champions Oncology in the previous year, attributing disappointing financial results to a combination of external and internal factors. Externally, the biotech sector’s weakness and retraction, along with tightness in the capital markets, impacted customer R&D budgets, leading to a decline in bookings growth and revenue. Internally, operational issues resulted in cost inefficiencies and delays in revenue recognition.

Despite these challenges, Morris highlighted the company’s strong finish to the year, with improvements in operations and signs of easing external pressures. The positive momentum continued into the current fiscal year, with increased revenue, improved operational efficiency, and scalability. Morris expressed optimism about the company’s turnaround and its potential for sustainable revenue and profitability.

Champions Oncology’s business is driven by its unique PDX bank, data analytics, and expanded platforms, offering insights for drug development. The company’s drug development subsidiary, Corellia, remains a focus, with discussions ongoing for out-licensing programs to support growth and development.

Miller then delved into the financial results for the first quarter of 2025. The company reported revenue of $14.1 million, a 12% increase from the previous year, marking a second consecutive quarter of revenue exceeding $14 million. The income from operations showed improvement, with adjusted EBITDA reaching $2 million, compared to a loss in the year-ago period.

Operational efficiencies led to a decline in total cost of sales and improved gross margins. In addition, R&D expenses were strategically reduced, with investments focused on core business areas. The company ended the quarter with $2.9 million in cash and no debt, signaling financial stability and the potential for future growth.

Overall, Champions Oncology’s first quarter results demonstrated positive trends in revenue, operational performance, and financial stability. The company remains focused on delivering value to shareholders and building on the momentum achieved in recent quarters. With a strong team and a commitment to innovation, Champions Oncology aims to continue its growth trajectory in the coming months.